Haemophilus influenzae

"HIB" redirects here. For the university college, see Bergen University College. For other uses of Hib, see Hib (disambiguation).

Not to be confused with HIV.

Haemophilus influenzae (formerly called Pfeiffer's bacillus or Bacillus influenzae) is a Gram-negative, non-motile, coccobacillary, facultatively anaerobic, capnophilic pathogenic bacterium of the family Pasteurellaceae. The bacteria are mesophilic and grow best at temperatures between 35 and 37 °C.^[1]

Haemophilus influenzae
H. influenzae on a chocolate agar plate
Scientific classification
Domain:	Bacteria
Phylum:	Pseudomonadota
Class:	Gammaproteobacteria
Order:	Pasteurellales
Family:	Pasteurellaceae
Genus:	Haemophilus
Species:	H. influenzae
Binomial name
Haemophilus influenzae (Lehmann & Neumann 1896) Winslow et al. 1917

H. influenzae was first described in 1893^[2][3] by Richard Pfeiffer during an influenza pandemic^[4] when he incorrectly identified it as the causative microbe, which is why the bacteria was given the name "influenzae".^[5][6] H. influenzae is responsible for a wide range of localized and invasive infections, typically in infants and children,^[7] including pneumonia, meningitis, or bloodstream infections.^[8] Treatment consists of antibiotics; however, H. influenzae is often resistant to the penicillin family, but amoxicillin/clavulanic acid can be used in mild cases.^[9] Serotype B H. influenzae have been a major cause of meningitis in infants and small children, frequently causing deafness and mental retardation. However the development in the 1980s of a vaccine effective in this age group (the Hib vaccine) has almost eliminated this in developed countries.

This species was the first organism to have its entire genome sequenced.^[10][11]

Physiology and metabolism

Structure

H. influenzae is a small Gram-negative bacterium, approximately 0.3 micrometer to 1 micrometer.^[12] Like other Gram-negative bacteria, H. influenzae has a thin peptidoglycan layer surrounded by an outer membrane containing lipopolysaccharide.^[13] Some types of H. influenzae contain a polysaccharide capsule around the outer membrane to aid in protection and colonization.^[14] The bacteria are pleomorphic, meaning the shape of the bacterium is variable, however it is typically coccobacillus or rod-shaped.^[15] H. Influenzae contains pili, which are specialized to adhere to the human nasopharynx. The H. Influenzae pili, unlike those of E. coli, resist unwinding, allowing for stronger adhesion to resist expulsion when coughing or sneezing.^[16] A minority of non-typeable, or unencapsulated, H. influenzae employ a variety of attachment techniques, such as pili, adhesins, or Hia and Hap proteins.^[17] Though the bacteria possess pili, they are not used for traditional movement or motility, and the bacterium is still considered to be non-motile.^[18]

The cell wall of H. influenzae bacterium contains various proteins, referred to as autotransporters, for adherence and colony formation. H. influenzae prefers to bind to mucus linings or non-ciliated epithelial cells, which is facilitated by Hap𝘴 autotransporters in the cell wall binding with unknown receptors within the epithelium.^[19] The Hap𝘴 autotransporters also facilitate the formation of microcolonies of the bacteria. These microcolonies are likely responsible for the formation of various biofilms within the body, such as those responsible for middle ear or lung infections.^[19]

Penicillin binding proteins

Penicillin binding proteins (PBPs) catalyze steps in peptidoglycan metabolism. They carry out essential processes needed to build and modify the cell wall.^[20] These proteins are the targets blocked by penicillin and other beta-lactam antibiotics that bind to PBPs, hence their name.^[21] Some antibiotic-resistant isolates of H. Influenzae contain modified PBPs that resist beta-lactam action by producing beta-lactamases to degrade these antibiotics. This resistance is likely due to a N526K mutation, or R517H substitution in conjunction with another unknown mutation. The R517H substitution alone did not have a lower affinity for penicillin, and therefore cannot cause resistance alone.^[20] Beta-lactamase emergence in the 1970s caused the therapy for severe cases of H. influenzae to be changed from ampicillin to cephalosporins, however further resistance to cephalosporins has occurred due to changes in the transpeptidase domain of penicillin binding protein 3 (PBP3).^[22]

Serotypes

H. influenzae isolates were initially characterized as either encapsulated (having an extracellular polysaccharide layer, the bacterial capsule) or unencapsulated. Encapsulated strains were further classified on the basis of the immune response to the type of polysaccharides in their capsule. The six generally recognized types of encapsulated H. influenzae are: a, b, c, d, e, and f.^[23] H. Influenzae type b, also known as Hib, is the most common form, recognizable by its polyribosyl ribitol phosphate (PRP) capsule, and found mostly in children.^[24] Types a, e, and f have been isolated infrequently, while types d and c are rarely isolated. Unencapsulated strains are more genetically diverse than the encapsulated group.^[25] Unencapsulated strains are termed nontypable (NTHi) because they lack capsular serotypes; however, all H. influenzae isolates can now be classified by multilocus sequence typing and other molecular methods. Most NTHi strains are considered to be part of the normal human flora in the upper and lower respiratory tract, genitals, and conjunctivae (mucous membranes of the eye).^[24]

Metabolism

H. influenzae uses the Embden–Meyerhof–Parnas (EMP) pathway for glycolysis and the pentose phosphate pathway, which is anabolic rather than catabolic. The citric acid cycle is incomplete and lacks several enzymes that are found in a fully functioning cycle. The enzymes missing from the TCA cycle are citrate synthase, aconitate hydratase, and isocitrate dehydrogenase.^[26] H. influenzae has been found in both aerobic and anaerobic environments, as well as environments with different pH's.^[27]

Genome and genetics

H. influenzae was the first free-living organism to have its entire genome sequenced. Completed by Craig Venter and his team at The Institute for Genomic Research, now part of the J. Craig Venter Institute. Haemophilus was chosen because one of the project leaders, Nobel laureate Hamilton Smith, had been working on it for decades and was able to provide high-quality DNA libraries. The sequencing method used was whole-genome shotgun, which was completed and published in Science in 1995.^[10]

The genome of strain Rd KW20 consists of 1,830,138 base pairs of DNA in a single circular chromosome that contains 1604 protein-coding genes, 117 pseudogenes, 57 tRNA genes, and 23 other RNA genes.^[10] About 90% of the genes have homologs in E. coli, another gamma-proteobacterium. In fact, the similarity between genes of the two species ranges from 18% to 98% protein sequence identity, with the majority sharing 40-80% of their amino acids (with an average of 59%).^[28]

Conjugative plasmids (DNA molecules that are capable of horizontal transfer between different species of bacteria) can frequently be found in H. influenzae. It is common that the F+ plasmid of a competent Escherichia coli bacterium conjugates into the H. influenzae bacterium, which then allows the plasmid to transfer among H. influenzae strands via conjugation.^[29]

Role of transformation

H. influenzae mutants defective in their rec1 gene (a homolog of recA) are very susceptible to being killed by the oxidizing agent hydrogen peroxide.^[30] This finding suggests that rec1 expression is important for H. influenzae survival under conditions of oxidative stress. Since it is a homolog of recA, rec1 likely plays a key role in recombinational repair of DNA damage. Thus, H. influenzae may protect its genome against the reactive oxygen species produced by the host's phagocytic cells through recombinational repair of oxidative DNA damages.^[31] Recombinational repair of a damaged site of a chromosome requires, in addition to rec1, a second homologous undamaged DNA molecule. Individual H. influenzae cells are capable of taking up homologous DNA from other cells by the process of transformation. Transformation in H. influenzae involves at least 15 gene products,^[10] and is likely an adaptation for repairing DNA damage in the resident chromosome.^[32]

Culture methods and diagnosis of infections

 

Sputum Gram stain at 1000x magnification. The sputum is from a person with Haemophilus influenzae pneumonia, and the Gram negative coccobacilli are visible with a background of neutrophils.

 

Haemophilus influenzae requires hemin and NAD for growth. In this culture, Haemophilus has only grown around the paper disc that has been impregnated with these factors. No bacterial growth is seen around the discs that only contain either hemin or NAD.

 

Chest X-ray of a case of Haemophilus influenzae, presumably as a secondary infection from influenza. It shows patchy consolidations, mainly in the right upper lobe (arrow).

 

Chest X-ray in a case of COPD exacerbation where a nasopharyngeal swab detected Haemophilus influenzae: Opacities (on the patient's right side) can be seen in other types of pneumonia, as well.

Culture

 

Haemophilus influenzae satellite colonies (pin points) near Staphylococcus aureus (yellow) on blood agar plate

Bacterial culture of H. influenzae is performed on agar plates. The strongest growth is seen on chocolate agar at 37 °C in a CO₂-enriched incubator.^[33] The ideal CO₂ concentration for the culture is ~5%.^[34] However adequate growth is often seen on brain-heart infusion agar supplemented with , with added hemin and nicotinamide adenine dinucleotide (NAD)

Colonies of H. influenzae appear as convex, smooth, pale, grey, or transparent colonies with a mild odor.^[34] H. influenzae will only grow on blood agar if other bacteria are present to release these factors from the red blood cells, forming 'satellite' colonies around these bacteria. For example, H. influenzae will grow in the hemolytic zone of Staphylococcus aureus on blood agar plates; the hemolysis of cells by S. aureus releases NAD which is needed for its growth. H. influenzae will not grow outside the hemolytic zone of S. aureus due to the lack of nutrients in these areas.^[35]

Diagnosis of infections

Clinical features of a respiratory tract infection may include initial symptoms of an upper respiratory tract infection mimicking a viral infection, usually associated with low-grade fevers. This may progress to the lower respiratory tract within a few days, with features often resembling those of wheezy bronchitis. Sputum may be difficult to expectorate and is often grey or creamy in color. The cough may persist for weeks without appropriate treatment. Many cases are diagnosed after presenting chest infections that do not respond to penicillins or first-generation cephalosporins. A chest X-ray can identify alveolar consolidation.^[36]

Clinical diagnosis of invasive H. influenzae infection (infection that has spread to the bloodstream and internal tissues) is typically confirmed by bacterial culture, latex particle agglutination tests, or polymerase chain reaction tests on clinical samples obtained from an otherwise sterile body site. In this respect, H. influenzae cultured from the nasopharyngeal cavity or throat would not indicate H. influenzae disease, because these sites are colonized in disease-free individuals.^[37] However, H. influenzae isolated from cerebrospinal fluid or blood or joint fluid would indicate invasive H. influenzae infection.Microscopic observation of a Gram stained specimen of H. influenzae will show Gram-negative coccobacillus. The cultured organism can be further characterized using catalase and oxidase tests, both of which should be positive. Further serological testing is necessary to distinguish the capsular polysaccharide and differentiate between H. influenzae b and nonencapsulated strains.^{[citation needed]}

Although highly specific, bacterial culture of H. influenzae lacks sensitivity. Use of antibiotics prior to sample collection greatly reduces the isolation rate by killing the bacteria before identification is possible.^[38] Recent work has shown that H. influenzae uses a highly specialized spectrum of nutrients where lactate is a preferred carbon source.^[39]

Latex particle agglutination

The latex particle agglutination test (LAT) is a more sensitive method to detect H. influenzae than is culture.^[40] Because the method relies on antigen rather than viable bacteria, the results are not disrupted by prior antibiotic use. It also has the added benefit of being quicker than culture methods. However, antibiotic sensitivity testing is not possible with LAT alone, so a parallel culture is necessary.^[41]

Molecular methods

Polymerase chain reaction (PCR) assays have been proven to be more sensitive than either LAT or culture tests and are highly specific.^[42] These PCR tests can be used for capsular typing of encapsulated H. influenzae strains.^[43]

Pathogenicity

Host colonization

Many microbes colonize within a host organism. Colonization occurs when a microorganism continues to multiply within the host, without interaction, causing no visible signs of illness or infection. H. influenzae colonizes differently in adults than it does young children. Because this bacterium colonizes more rapidly in young children, they are capable of carrying more than one strain of the same bacterium. Once in the adult stage of life, a human is likely to only be carrying one strain as this bacterium does not colonize as aggressively in adults. Nearly all infants will undergo colonization of this bacteria within their first year of life.^[17]

H. influenzae is generally found within and upon the human body, but can also live on various dry, hard surfaces for up to 12 days.^[44][45] Most strains of H. influenzae are opportunistic pathogens; that is, they usually live in their host without causing disease, but cause problems only when other factors (such as a viral infection, reduced immune function or chronically inflamed tissues, e.g. from allergies) create an opportunity. They infect the host by sticking to the host cell using trimeric autotransporter adhesins.^[46]

The pathogenesis of H. influenzae infections is not completely understood, although the presence of the polyribosyl ribitol phosphate (PRP) capsule in encapsulated type b (Hib), a serotype causing conditions such as epiglottitis, is known to be a major factor in virulence.^[47] Their capsule allows them to resist phagocytosis and complement-mediated lysis in the nonimmune host. The unencapsulated strains are almost always less invasive; however, they can produce an inflammatory response in humans, which can lead to many symptoms. Vaccination with Hib conjugate vaccine is effective in preventing Hib infection but does not prevent infection with NTHi strains.^[48]

H. influenzae can cause respiratory tract infections including pneumonia, otitis media, epiglottitis (swelling in the throat), eye infections and bloodstream infection, meningitis. It can also cause cellulitis (skin infection) and infectious arthritis (inflammation of the joint).^[49]

Haemophilus influenzae type b (Hib) infection

Naturally acquired disease caused by H. influenzae seems to occur in humans only. In healthy children under the age of 5, H. influenzae type b was responsible for more than 80% of aggressive infections, before the introduction of the [Hib] vaccine.^[50] In infants and young children, H. influenzae type b (Hib) causes bacteremia, pneumonia, epiglottitis and acute bacterial meningitis.^[51] On occasion, it causes cellulitis, osteomyelitis, and infectious arthritis. It is one cause of neonatal infection.^[52]

Due to routine use of the Hib vaccine in the U.S. since 1990, the incidence of invasive Hib disease has decreased to 1.3/100,000 in children.^[51] However, Hib remains a major cause of lower respiratory tract infections in infants and children in developing countries where the vaccine is not widely used. Unencapsulated H. influenzae strains are unaffected by the Hib vaccine and cause ear infections (otitis media), eye infections (conjunctivitis), and sinusitis in children, and are associated with pneumonia.^[51]

Treatment

Some strains of H. influenzae produce beta-lactamases, and are also able to modify its penicillin-binding proteins, so the bacteria have gained resistance to the penicillin family of antibiotics. In severe cases, cefotaxime and ceftriaxone delivered directly into the bloodstream are the elected antibiotics, and, for the less severe cases, an association of ampicillin and sulbactam, cephalosporins of the second and third generation, or fluoroquinolones are preferred. (Fluoroquinolone-resistant strains of H. influenzae have been observed).^[53]

Macrolides and fluoroquinolones have activity against non-typeable H. influenzae and could be used in patients with a history of allergy to beta-lactam antibiotics.^[54] However, macrolide resistance has also been observed.^[55]

Serious and chronic complications

The serious complications of HiB are brain damage, hearing loss, and even death. While non-typable H. influenzae strains rarely cause serious disease, they are more likely to cause chronic infections because they have the ability to change their surface antigens. Chronic infections are usually not as serious as acute infections.^[56]

There are a few other possible diseases and conditions that can arise from the H. influenzae depending on the areas that they exist in within the human body. This bacterium can exist in the nasal passages (especially the nasopharynx), the ear canal, and the lungs. The bacterium's presence in these areas can lead to some conditions such as otitis media, chronic obstructive pulmonary disorder (COPD), epiglottitis, and asthma which can become severe.^[27]

Vaccination

 

ActHIB (Hib-vaccine)

Effective vaccines for Haemophilus influenzae serotype b have been available since the early 1990s, and are recommended for children under age 5 and asplenic patients. The World Health Organization recommends a pentavalent vaccine, combining vaccines against diphtheria, tetanus, pertussis, hepatitis B and Hib. There is not yet sufficient evidence on how effective this pentavalent vaccine is in relation to the individual vaccines.^[57]

Hib vaccines cost about seven times the total cost of vaccines against measles, polio, tuberculosis, diphtheria, tetanus, and pertussis. Consequently, whereas 92% of the populations of developed countries were vaccinated against Hib as of 2003, vaccination coverage was 42% for developing countries, and only 8% for least-developed countries.^[58]

The Hib vaccines do not provide cross-protection to any other H. influenzae serotypes like Hia, Hic, Hid, Hie or Hif.^[59]

An oral vaccination has been developed for non-typeable H. influenzae (NTHi) for patients with chronic bronchitis, but it has not shown to be effective in reducing the number and severity of COPD exacerbations.^[60] However, there is no effective vaccine for the other types of capsulated H. influenzae or NTHi.^{[citation needed]}

Vaccines that target unencapsulated H. influenzae serotypes are in development.^[61]

See also

•  Biology portal

• Hattie Alexander
• Haemophilus influenzae cellulitis
• Haemophilus meningitis
• Maurice Hilleman
• Trimeric Autotransporter Adhesins (TAA)

References

1. "Meningitis, Hib and Pneumococcal Conjugate Vaccines". AAP Grand Rounds. 3 (1): 3–4. 2000-01-01. doi:10.1542/gr.3-1-3-a. ISSN 1099-6605.
2. Pfeiffer, R (1893). "Die Aetiologie der Influenza". Zeitschrift für Hygiene und Infektionskrankheiten. 13: 357–385. doi:10.1007/BF02284284. S2CID 38511538.
3. "Deep Blue: Search". deepblue.lib.umich.edu.
4. Kuhnert P, Christensen H, eds. (2008). Pasteurellaceae: Biology, Genomics and Molecular Aspects. Caister Academic Press. ISBN 978-1-904455-34-9.
5. Morens DM, Taubenberger JK, Folkers GK, Fauci AS (December 2010). "Pandemic influenza's 500th anniversary". Clinical Infectious Diseases. 51 (12): 1442–1444. doi:10.1086/657429. PMC 3106245. PMID 21067353.
6. Taubenberger JK, Hultin JV, Morens DM (2007). "Discovery and characterization of the 1918 pandemic influenza virus in historical context". Antiviral Therapy. 12 (4 Pt B): 581–591. doi:10.1177/135965350701200S02.1. PMC 2391305. PMID 17944266.
7. "Pinkbook: Haemophilus influenzae (Hib) | CDC". www.cdc.gov. 2022-09-22. Retrieved 2022-10-13.
8. "Symptoms of Haemophilus influenzae | CDC". www.cdc.gov. 2022-04-04. Retrieved 2022-10-20.
9. Chang AB, Upham JW, Masters IB, Redding GR, Gibson PG, Marchant JM, Grimwood K (March 2016). "Protracted bacterial bronchitis: The last decade and the road ahead". Pediatric Pulmonology. 51 (3): 225–242. doi:10.1002/ppul.23351. PMC 7167774. PMID 26636654.
10. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, et al. (July 1995). "Whole-genome random sequencing and assembly of Haemophilus influenzae Rd". Science. 269 (5223): 496–512. Bibcode:1995Sci...269..496F. doi:10.1126/science.7542800. PMID 7542800. S2CID 10423613.
11. "About J. Craig Venter Institute". J. Craig Venter Institute.
12. Khattak ZE, Anjum F (2022), "Haemophilus Influenzae", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32965847, retrieved 2022-10-27
13. Silhavy TJ, Kahne D, Walker S (May 2010). "The bacterial cell envelope". Cold Spring Harbor Perspectives in Biology. 2 (5): a000414. doi:10.1101/cshperspect.a000414. PMC 2857177. PMID 20452953.
14. Sukupolvi-Petty S, Grass S, St Geme JW (June 2006). "The Haemophilus influenzae Type b hcsA and hcsB gene products facilitate transport of capsular polysaccharide across the outer membrane and are essential for virulence". Journal of Bacteriology. 188 (11): 3870–3877. doi:10.1128/JB.01968-05. PMC 1482897. PMID 16707679.
15. "Meningitis Lab Manual: ID and Characterization of Hib | CDC". www.cdc.gov. 2022-01-05. Retrieved 2022-10-04.
16. Mu XQ, Egelman EH, Bullitt E (September 2002). "Structure and function of Hib pili from Haemophilus influenzae type b". Journal of Bacteriology. 184 (17): 4868–4874. doi:10.1128/JB.184.17.4868-4874.2002. PMC 135281. PMID 12169612.
17. King P (June 2012). "Haemophilus influenzae and the lung (Haemophilus and the lung)". Clinical and Translational Medicine. 1 (1): 10. doi:10.1186/2001-1326-1-10. PMC 3567431. PMID 23369277.
18. Johnston, Jason W. (August 2010). "Laboratory growth and maintenance of Haemophilus influenzae". Current Protocols in Microbiology. Chapter 6: Unit 6D.1. doi:10.1002/9780471729259.mc06d01s18. ISSN 1934-8533. PMID 20812218. S2CID 37003711.
19. Spahich, Nicole; St. Geme, III, Joseph (2011). "Structure and function of the Haemophilus influenzae autotransporters". Frontiers in Cellular and Infection Microbiology. 1: 5. doi:10.3389/fcimb.2011.00005. ISSN 2235-2988. PMC 3417375. PMID 22919571.{{cite journal}}: CS1 maint: multiple names: authors list (link)
20. Parsons JF, Lim K, Tempczyk A, Krajewski W, Eisenstein E, Herzberg O (March 2002). "From structure to function: YrbI from Haemophilus influenzae (HI1679) is a phosphatase". Proteins. 46 (4): 393–404. doi:10.1002/prot.10057. PMC 3762886. PMID 11835514.
21. Malouin F, Parr TR, Bryan LE (February 1990). "Identification of a group of Haemophilus influenzae penicillin-binding proteins that may have complementary physiological roles". Antimicrobial Agents and Chemotherapy. 34 (2): 363–365. doi:10.1128/AAC.34.2.363. PMC 171589. PMID 2327782.
22. Skaare D, Anthonisen IL, Kahlmeter G, Matuschek E, Natås OB, Steinbakk M, et al. (December 2014). "Emergence of clonally related multidrug resistant Haemophilus influenzae with penicillin-binding protein 3-mediated resistance to extended-spectrum cephalosporins, Norway, 2006 to 2013". Euro Surveillance. 19 (49): 20986. doi:10.2807/1560-7917.ES2014.19.49.20986. hdl:10037/7128. PMID 25523969.
23. Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 396–401. ISBN 978-0-8385-8529-0.
24. Khattak ZE, Anjum F (2022). "Haemophilus Influenzae". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32965847. Retrieved 2022-10-27.
25. LaCross, Nathan C.; Marrs, Carl F.; Patel, Mayuri; Sandstedt, Sara A.; Gilsdorf, Janet R. (November 2008). "High Genetic Diversity of Nontypeable Haemophilus influenzae Isolates from Two Children Attending a Day Care Center". Journal of Clinical Microbiology. 46 (11): 3817–3821. doi:10.1128/jcm.00940-08. ISSN 0095-1137. PMC 2576570. PMID 18845825.
26. Harrison A, Hardison RL, Wallace RM, Fitch J, Heimlich DR, Bryan MO, et al. (2019-11-05). "Reprioritization of biofilm metabolism is associated with nutrient adaptation and long-term survival of Haemophilus influenzae". npj Biofilms and Microbiomes. 5 (1): 33. doi:10.1038/s41522-019-0105-6. PMC 6831627. PMID 31700653.
27. Othman, Dk Seti Maimonah Pg; Schirra, Horst; McEwan, Alastair G.; Kappler, Ulrike (2014-03-04). "Metabolic versatility in Haemophilus influenzae: a metabolomic and genomic analysis". Frontiers in Microbiology. 5: 69. doi:10.3389/fmicb.2014.00069. ISSN 1664-302X. PMC 3941224. PMID 24624122.
28. Tatusov RL, Mushegian AR, Bork P, Brown NP, Hayes WS, Borodovsky M, et al. (March 1996). "Metabolism and evolution of Haemophilus influenzae deduced from a whole-genome comparison with Escherichia coli". Current Biology. 6 (3): 279–291. doi:10.1016/S0960-9822(02)00478-5. PMID 8805245. S2CID 14057384.
29. Poje G, Redfield RJ (2003). "Transformation of Haemophilus influenzae". In Herbert MA, Hood DW, Moxon ER (eds.). Hemophilus influenzae Protocols. Haemophilus influenzae Protocols. Vol. 71. Totowa, NJ: Humana Press. pp. 57–70. doi:10.1385/1-59259-321-6:57. ISBN 978-1-59259-321-7. PMID 12374031. {{cite book}}: |journal= ignored (help)
30. Sánchez-Rincón DA, Cabrera-Juárez E (October 1991). "Lethal and mutagenic action of hydrogen peroxide on Haemophilus influenzae". Journal of Bacteriology. 173 (20): 6632–6634. doi:10.1128/jb.173.20.6632-6634.1991. PMC 209002. PMID 1917884.
31. Michod RE, Bernstein H, Nedelcu AM (May 2008). "Adaptive value of sex in microbial pathogens". Infection, Genetics and Evolution. 8 (3): 267–285. doi:10.1016/j.meegid.2008.01.002. PMID 18295550. As PDF
32. Bernstein H, Bernstein C, Michod RE. Sex in microbial pathogens. Infect Genet Evol. 2018 Jan;57:8-25. doi: 10.1016/j.meegid.2017.10.024. Epub 2017 Oct 27. PMID 29111273
33. Levine OS; Schuchat A; Schwartz B; Wenger JD; Elliott J; Centers for Disease Control (1997). (PDF). World Health Organization. WHO/VRD/GEN/95.05. Archived from the original (PDF) on July 1, 2004.
34. "Meningitis Lab Manual: ID and Characterization of Hib | CDC". www.cdc.gov. 2022-01-05. Retrieved 2022-09-21.
35. Xi Y, Wang H, Wang S, Wu X, Wang Z (February 2022). "A study of various factors affecting satellitism tests of Haemophilus influenzae and Haemophilus parainfluenzae using Staphylococcus aureus as the source of NAD". Journal of Microbiological Methods. 193: 106417. doi:10.1016/j.mimet.2022.106417. PMID 35033634. S2CID 245957339.
36. "Measuring impact of Streptococcus pneumoniae and Haemophilus influenzae type b conjugate vaccination" (PDF). World Health Organization. September 2012
37. Puri J, Talwar V, Juneja M, Agarwal KN, Gupta HC (October 1999). "Prevalence of anti-microbial resistance among respiratory isolates of Haemophilus influenzae". Indian Pediatrics. 36 (10): 1029–1032. PMID 10745313.
38. John TJ, Cherian T, Steinhoff MC, Simoes EA, John M (1991). "Etiology of acute respiratory infections in children in tropical southern India". Reviews of Infectious Diseases. 13 (Suppl 6): S463–S469. doi:10.1093/clinids/13.supplement_6.s463. PMID 1862277.
39. Hosmer J, Nasreen M, Dhouib R, Essilfie AT, Schirra HJ, Henningham A, et al. (January 2022). "Access to highly specialized growth substrates and production of epithelial immunomodulatory metabolites determine survival of Haemophilus influenzae in human airway epithelial cells". PLOS Pathogens. 18 (1): e1010209. doi:10.1371/journal.ppat.1010209. PMC 8794153. PMID 35085362.
40. Kennedy WA, Chang SJ, Purdy K, Le T, Kilgore PE, Kim JS, et al. (October 2007). "Incidence of bacterial meningitis in Asia using enhanced CSF testing: polymerase chain reaction, latex agglutination and culture". Epidemiology and Infection. 135 (7): 1217–1226. doi:10.1017/S0950268806007734. PMC 2870670. PMID 17274856.
41. Camargos PA, Almeida MS, Cardoso I, Filho GL, Filho DM, Martins JI, et al. (October 1995). "Latex particle agglutination test in the diagnosis of Haemophilus influenzae type B, Streptococcus pneumoniae and Neisseria meningitidis A and C meningitis in infants and children". Journal of Clinical Epidemiology. 48 (10): 1245–1250. doi:10.1016/0895-4356(95)00016-w. PMID 7561986.
42. Diallo K, Feteh VF, Ibe L, Antonio M, Caugant DA, du Plessis M, et al. (March 2021). "Molecular diagnostic assays for the detection of common bacterial meningitis pathogens: A narrative review". eBioMedicine. 65: 103274. doi:10.1016/j.ebiom.2021.103274. PMC 7957090. PMID 33721818.
43. Buensalido JA, Malundo AF, Devarajan VR, Lim BA, Emmons WW (2021-06-26). Talavera F, Sanders CV (eds.). "Haemophilus Influenzae Infections: Practice Essentials, Background, Pathophysiology". Medscape.
44. "Haemophilus Influenzae". Health Department. Retrieved 2022-11-16.
45. Kramer A, Schwebke I, Kampf G (August 2006). "How long do nosocomial pathogens persist on inanimate surfaces? A systematic review". BMC Infectious Diseases. 6: 130. doi:10.1186/1471-2334-6-130. PMC 1564025. PMID 16914034.
46. "Haemophilus influenzae Disease (Including Hib)". Centers For Disease Control And Prevention. 18 March 2021. Retrieved 20 July 2021.
47. Buensalido JA, Malundo AF, Devarajan VR, Lim BA, Emmons WW (26 June 2021). Talavera F, Sanders CV (eds.). . Medscape. Archived from the original on 2 December 2021.
48. Slack MP, Azzopardi HJ, Hargreaves RM, Ramsay ME (September 1998). "Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines". The Pediatric Infectious Disease Journal. 17 (9 Suppl): S204–S207. doi:10.1097/00006454-199809001-00026. PMID 9781764.
49. "Signs and Symptoms". Centers for Disease Control and Prevention (CDC). 2019-01-24.
50. Ladhani S, Slack MP, Heath PT, von Gottberg A, Chandra M, Ramsay ME (March 2010). "Invasive Haemophilus influenzae Disease, Europe, 1996-2006". Emerging Infectious Diseases. 16 (3): 455–463. doi:10.3201/eid1603.090290. PMC 3322004. PMID 20202421.
51. "Epiglottitis". The Lecturio Medical Concept Library. 22 June 2020. Retrieved 20 July 2021.
52. Baucells BJ, Mercadal Hally M, Álvarez Sánchez AT, Figueras Aloy J (November 2016). "[Probiotic associations in the prevention of necrotising enterocolitis and the reduction of late-onset sepsis and neonatal mortality in preterm infants under 1,500g: A systematic review]". Anales de Pediatria. 85 (5): 247–255. doi:10.1016/j.anpedi.2015.07.038. PMID 26611880.
53. Chang CM, Lauderdale TL, Lee HC, Lee NY, Wu CJ, Chen PL, et al. (August 2010). "Colonisation of fluoroquinolone-resistant Haemophilus influenzae among nursing home residents in southern Taiwan". The Journal of Hospital Infection. 75 (4): 304–308. doi:10.1016/j.jhin.2009.12.020. PMID 20356651.
54. Murphy TF (2020). "Haemophilus Species, Including H. influenzae and H. ducreyi (Chancroid)". Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (9th ed.). Philadelphia, PA: Elsevier. ISBN 978-0-323-48255-4.
55. Roberts MC, Soge OO, No DB (January 2011). "Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis". The Journal of Antimicrobial Chemotherapy. 66 (1): 100–104. doi:10.1093/jac/dkq425. PMID 21081549.
56. "Serious Complications-CDC website". www.cdc.gov.
57. Bar-On ES, Goldberg E, Hellmann S, Leibovici L (April 2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". The Cochrane Database of Systematic Reviews. 4 (4): CD005530. doi:10.1002/14651858.CD005530.pub3. PMID 22513932.
58. "Haemophilus influenzae type B (HiB)". Health Topics A to Z. Retrieved 2011-03-29.
59. Jin Z, Romero-Steiner S, Carlone GM, Robbins JB, Schneerson R (June 2007). "Haemophilus influenzae type a infection and its prevention". Infection and Immunity. 75 (6): 2650–2654. doi:10.1128/IAI.01774-06. PMC 1932902. PMID 17353280.
60. Teo E, Lockhart K, Purchuri SN, Pushparajah J, Cripps AW, van Driel ML (June 2017). "Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews. 2017 (6): CD010010. doi:10.1002/14651858.CD010010.pub3. PMC 6481520. PMID 28626902.
61. "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction". ClinicalTrials.gov. 2014-02-27. Retrieved 2016-09-20.

External links

 

Wikimedia Commons has media related to Haemophilus influenzae.

• Hib information on the World Health Organization (WHO) site.
• Fact sheet on the Centers for Disease Control and Prevention (CDC) site.
• —from Johns Hopkins University, London School of Hygiene & Tropical Medicine, CDC & WHO
• Centers for Disease Control and Prevention (2012). . In Atkinson W; Wolfe S; Hamborsky J (eds.). Epidemiology and Prevention of Vaccine-Preventable Diseases (12th ed.). Washington, D.C.: Public Health Foundation. pp. 87–100. Archived from the original on 2017-03-10.
• "Haemophilus influenzae". NCBI Taxonomy Browser. 727.
• Type strain of Haemophilus influenzae at BacDive – the Bacterial Diversity Metadatabase